Eir Partners Acquires Accumulus to Scale Life Sciences
San Francisco, California, USA, September 9, 2026 Eir Partners has acquired Accumulus Technologies, marking a new phase of growth...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Francisco, California, USA, September 9, 2026 Eir Partners has acquired Accumulus Technologies, marking a new phase of growth...
Mumbai, India, and Naples, Florida, USA, September 4, 2026 Lupin Limited has received U.S. Food and Drug Administration (FDA)...
Incheon, South Korea, September 3, 2026 Samsung Bioepis has announced that its ustekinumab biosimilar has received marketing approval in...
DULUTH, Georgia, August 12, 2026 Bridge to Life Ltd., a medical technology company specializing in organ preservation and perfusion...
INDIANAPOLIS, Indiana, August 12, 2026 Eli Lilly and Company has intensified its efforts to combat the illegal sale of...
WESTON, FLORIDA, April 27, 2026 Apotex has secured U.S. Food and Drug Administration (FDA) approval for its generic Infuvite®...
Washington, D.C., United States – March 10, 2026 The U.S. Food and Drug Administration (FDA) has released updated draft...
